Last summer, a group of leading biotech entrepreneurs in Silicon Valley described work that struck their visitor as close to magic. Using advanced science combined with artificial intelligence, they are looking for ways to repair damaged cells in human organs. Their ambitions reach as far as the brain, and some of them talk openly about a future in which people no longer die of age-related decline. What surprised the visitor was that none of them mentioned China until he raised the subject himself.
Once asked, the entrepreneurs pointed to two advantages that they considered hard to match. The first is access to very large volumes of health data. Chinese researchers can work with datasets, and with consent rules on sensitive material such as fetal tissue, that would be politically or ethically difficult in the West. They did not argue that Western countries should copy this approach. Their point was that governments and companies need to understand these trade-offs and map their consequences clearly.
The second advantage is speed. Several of the entrepreneurs said that China can move drugs, medical devices and new technologies through regulation in a third of the usual time, or less. One of them put the economics bluntly: a drug that clears development in a third of the time starts with a cost advantage of roughly one billion dollars. He added that this figure came before the labs, suppliers and manufacturing networks that China has built into its system from the outset. None of the people interviewed had evidence that the faster process produced unsafe outcomes.
Speed, manufacturing and the regulatory model
The speed comes partly from culture. Chinese populations have a different attitude toward medical risk than many Western populations, and that shapes how quickly people accept new treatments. Ruby Wang, who spent the first decade of her career in the British health system and now runs the consultancy LINTRIS Health, argues that the speed also comes from a regulatory system that is precise, increasingly tech-enabled and focused on getting products to patients.
Her view is that the advantage lies in the wider ecosystem, not only in faster approvals. Biotech companies in China work within dense clusters of scientists, manufacturers, hospitals, investors and service providers. Clinical trials can recruit patients more quickly, production costs are lower, and researchers can move between laboratory work and clinical testing with fewer logistical obstacles. Wuxi, a manufacturing city about 70 miles from Shanghai that has long been known for electronics, is now one of the most important centers for end-to-end pharmaceutical and life sciences production. American pharmaceutical executives visiting the city described their dependence on it in blunt terms: ‘We simply need them, full stop.’
Regulatory reform has also played a role. According to Wang, China has overhauled its drug approval system since 2015, worked through large historical backlogs and aligned much of its clinical development framework with international standards. The country has also introduced a 30-working-day review pathway for eligible innovative drug trial applications.
Where China leads and where it still lags
China’s strongest area is oncology. Companies there have become skilled at taking promising scientific approaches, improving them, combining mechanisms and moving candidates through clinical development quickly. Antibody-drug conjugates, which deliver potent drugs directly to cancer cells, and bispecific antibodies, which target two biological pathways at once, are examples of technologies that reward the combination of molecular engineering, fast experimentation and clinical research capacity that China has developed.
Akeso’s ivonescimab marked a turning point in the industry’s view of Chinese biotech. Its Phase III trial showed better progression-free survival than Merck’s Keytruda in a particular group of lung cancer patients. Chinese-developed therapies now present late-stage data at international meetings such as ASCO and ESMO. Over the past decade, the announced value of Chinese pharmaceutical out-licensing deals has grown more than fiftyfold.
Progress is uneven across therapeutic areas. Chronic immunological diseases, neurological disorders and rare diseases involve more complex biology, harder patient recruitment and slower outcomes, and China’s capabilities there remain limited. The country is also still building the experience needed to consistently turn early discoveries into globally approved medicines.
The COVID-19 vaccine record shows both strengths and weaknesses. In 2020, China’s early vaccines, including those from Sinovac and Sinopharm, used established inactivated-virus technology that could be produced at scale. They protected against severe disease and mattered greatly for developing countries that could not easily obtain Western mRNA vaccines. The mRNA vaccines from Pfizer-BioNTech and Moderna, however, offered stronger protection against symptomatic infection as variants emerged. Chinese inactivated vaccines generated weaker immune responses, and older people needed additional doses. Wang notes that the initial choice was reasonable given the uncertainty of that year. The problem came later, when China kept relying on domestic vaccines and did not approve foreign mRNA vaccines for mainland use. When Zero-COVID restrictions ended in late 2022, many vulnerable older people remained poorly protected.
AI, robotics and the case for collaboration
Wang sees AI changing three areas: how medicines are discovered, how care is delivered and how medical technologies connect the two. In drug discovery, companies such as Insilico Medicine and XtalPi combine AI, computational modelling and automated laboratories to speed up parts of the process. AI could strengthen China’s existing habits of rapid iteration and low-cost experimentation, since cheaper tests allow researchers to pursue more hypotheses and reach promising candidates earlier.
In healthcare delivery, Chinese consumers already use mobile platforms for payments, shopping and services, which makes health apps easier to adopt. Ant Group’s Afu platform, based in Hangzhou, combines AI-assisted health advice, consultations and daily health management. Hospitals also use AI for imaging, documentation and diagnostic support. Wang is careful to separate Chinese products from Chinese methods. Products may travel abroad, but the way China tests these tools inside existing health systems may be the more useful lesson for other countries.
Robotics and affordable devices form another strand. Shenzhen’s electronics and sensor industries support companies such as MicroPort, whose Toumai surgical robot now competes with established international platforms. Chinese manufacturers are also producing lower-cost equipment, including portable ultrasound systems, for resource-limited health systems in places such as Africa. Wang believes that combining frontier engineering with manufacturing scale could bring advanced technologies to many more patients. Devices still have to prove safety, clinical benefit and long-term reliability.
Wang argues that competition and cooperation can coexist. Chinese biotech partnerships with Western drugmakers show that collaboration continues despite geopolitical tension. She wants easier international clinical trials, better mutual acceptance of high-quality evidence and more open sharing of research. Governments have legitimate concerns about sensitive technology and data security, she acknowledges, but those concerns should be applied precisely. Otherwise, fragmented research risks duplication, higher costs and slower progress for patients who are waiting for treatment.



